Companion diagnostic

Companion diagnostic
[[File:|250px|alt=|]]
Pronunciation
Synonyms
Reference Range
Calculator
Purpose	To determine the suitability of patients for specific treatments based on their genetic or biomarker status
Test of
Based on
ICD-10-PCS
ICD-9-CM
MeSH
OPS-301 Code
Other Codes
MedlinePlus
eMedicine
LOINC
HCPCS-L2

A companion diagnostic is a medical device, often an in vitro diagnostic test, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. These tests help to determine whether a particular therapeutic product's benefits to patients will outweigh any potential serious side effects or risks.

Overview

Companion diagnostics are primarily used in the field of personalized medicine, which tailors medical treatment to the individual characteristics of each patient. The test can help a healthcare provider determine whether a patient's genetic makeup or the expression of certain biomarkers makes them a good candidate for a specific medical therapy. This approach can be seen in treatments for diseases such as cancer, where the presence or absence of specific biomarkers can significantly impact the effectiveness of treatment.

Development and Regulation

The development of companion diagnostics is closely integrated with the development of the corresponding therapeutic product. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA), require evidence that the diagnostic is safe and effective before it can be marketed. In the United States, the FDA has guidelines that cover the co-development of therapeutic products and their companion diagnostics.

Applications

Companion diagnostics are most commonly used in oncology, to test for biomarkers such as gene mutations, gene expression, and specific proteins. For example, the detection of the HER2 protein in breast cancer cells can influence the use of trastuzumab, a targeted therapy for breast cancer. Other areas of medicine, such as infectious diseases and cardiovascular diseases, are also seeing increased use of companion diagnostics.

Challenges and Future Directions

The main challenges in the development of companion diagnostics include regulatory hurdles, the need for high levels of accuracy and reliability, and the complexities involved in developing tests that can be universally applied across different populations. Despite these challenges, the field of companion diagnostics is expected to grow, driven by advances in genomics, proteomics, and bioinformatics.

See Also

• Personalized medicine
• Pharmacogenomics
• Targeted therapy
• Biomarker (medicine)